International Stem Cell (OTCMKTS:ISCO – Get Free Report) released its quarterly earnings data on Monday. The biotechnology company reported ($0.04) EPS for the quarter, Zacks reports. The business had revenue of $2.15 million for the quarter.
International Stem Cell Stock Performance
ISCO traded up $0.01 on Tuesday, reaching $0.17. The company had a trading volume of 10,000 shares, compared to its average volume of 7,432. International Stem Cell has a fifty-two week low of $0.11 and a fifty-two week high of $0.27. The stock has a market cap of $1.36 million, a P/E ratio of -8.50 and a beta of 0.13. The company’s fifty day moving average is $0.15 and its 200 day moving average is $0.15.
About International Stem Cell
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Featured Stories
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
